Treeline is a clinical-stage biopharma focused on developing medicines for cancer and other serious diseases using internal R&D and leading-edge computational tools. Its pipeline includes small molecules, protein degraders and glues, and targeted therapy ADCs (TT‑ADCs). The company has initiated Phase 1 trials for three programs: TLN-121 (a BCL6 degrader for lymphomas), TLN-372 (a pan‑KRAS inhibitor for KRAS‑altered solid tumors), and TLN-254 (an in-licensed EZH2 inhibitor for T‑cell lymphomas). Treeline’s team and pipeline were built for scaled invention and company longevity and are led by co-founders Josh Bilenker, M.D., and Jeff Engelman. Therapeutic focus spans oncology with efforts also in neurological and autoimmune diseases. Financially, Treeline is privately held and has raised $1.1 billion to date, reflecting substantial capital to advance its clinical programs.

Total raised

$200M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2025